Trillium Therapeutics (NASDAQ:TRIL) Sees Unusually-High Trading Volume
Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) shares saw unusually-strong trading volume on Thursday . Approximately 4,766 shares changed hands during mid-day trading, a decline of 100% from the previous session’s volume of 1,036,931 shares.The stock last traded at $0.40 and had previously closed at $0.41.
A number of research analysts have commented on TRIL shares. Zacks Investment Research raised shares of Trillium Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research report on Thursday, April 25th. HC Wainwright decreased their target price on shares of Trillium Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a research report on Wednesday, March 13th.
The stock has a market cap of $7.85 million, a P/E ratio of -0.16 and a beta of 2.44.
About Trillium Therapeutics (NASDAQ:TRIL)
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
See Also: Swap
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.